Funding for this research was provided by:
National Natural Science Foundation of China (81361128006)
Shanghai Municipal Commission of Economy and Informatization (20184Y0256)
Received: 3 May 2021
Accepted: 19 September 2021
First Online: 9 October 2021
: This study was approved by the Ethics Committees on Human Research of the Children’s Hospital of Fudan University.
: Not applicable.
: KDRS and JEH have minor equity in Asklepion Pharmaceuticals and are consultants to Retrophin. JSW consulted for Ethyptharm. The other authors disclose no conflicts.